The following stocks (NASDAQ:OMER, NASDAQ:UNIS and NYSEMKT:AST) are oversold as their Relative Strength index (RSI) is below 30. Indeed, the RSI is one of the most popular technical indicators and is computed on the basis of the speed and direction of a stock’s price movement, generally in a 14-day window. The RSI value will always move between 0 and 100; the value will be 0 if the stock falls on all 14 days, and 100, if the price moves up on all the days. This implies that the RSI can also be used to identify the overbought/oversold levels. Most technical analysts consider the RSI value above 70 as ‘overbought zone’ and below 30 as ‘oversold zone’.
Omeros Corp (NASDAQ:OMER)(Trend analysis) relative strength index stands at 28.93. Omeros Corp (NASDAQ:OMER) stock is currently trading 38.13% below its 52-week-high, 52.95% above its 52-week-low. The 1-year stock price history is in the range of $11.18 – $27.64. Omeros Corp (OMER) has a price to book ratio of 29.38 versus Healthcare sector average of 123.65. Omeros Corp is currently valued at $0.65 billion. The stock has a 50-day moving average of $20.19 and a 200-day moving average of $22.15.
There are currently five analysts that cover Omeros Corp stock. Of those five, five have a Buy rating. On a consensus basis this yields to a Buy rating. The consensus target price stands at $40.25.
The stock closed last trading session at $17.1, up by 0.71%.
Unilife Corp (NASDAQ:UNIS)(Trend analysis) relative strength index is at the level of 26.64. The company’s shares were traded at $2, down by -4.76%, with a volume of 1,451,102 shares against an average volume for the last 3 months of 933,657. This represents a volume multiple of 1.55.
Unilife Corp (UNIS) current short interest stands at 24.21 million shares. It has increased by 3% from the same period of last month. Around 25% of the company’s shares, which are float, are short sold. With a 10-days average volume of 1.48 million shares, the number of days required to cover the short positions stand at 16.4 days.
A recent stock analyst activity consisted of Jefferies upgrading their Buy rating to on February 10. Jefferies decreased price target from $9 to $8.
Asterias Biotherapeutics Inc (NYSEMKT:AST)(Trend analysis) relative strength index is evolving around the 27 level. The stock closed last trading session at $4.35, up by 3.57%, with a volume of 854,712 shares compared to an average volume for the last 3 months of 316,271. The year-to-date performance of the stock stands at -40.3%.
Asterias Biotherapeutics Inc (AST) current short interest stands at 1.31 million shares. It has increased by 4% from the same period of last month. Around 19% of the company’s shares, which are float, are short sold. With a 10-days average volume of 0.75 million shares, the number of days required to cover the short positions stand at 1.8 days.